Flt3-ligand (FL) is
Introduction
Flt3-ligand (FL) is the ligand for the tyrosine kinase receptor, flt3/flk-2, a growth factor implicated in the regulation of early hematopoiesis. It has been shown to stimulate as a single agent the proliferation and the mobilization of stem and progenitor hematopoietic cells. In combination with other cytokines such as GM-CSF, G-CSF, IL-3, EPO, IL-11, IL-12, IL-6 or TPO, FL synergistically increases the proliferation of immature progenitors. FL is a potent agent for the expansion of LTC-IC. Hematopoietic cells mobilized with FL can reconstitute longterm hematopoiesis in lethally irradiated recipient mice. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Disruption of the flk2/flt3 gene leads to an alteration of the functional stem cell compartment in competitive repopulation assays. 15 In vitro normal primitive progenitors from the peripheral blood of chronic myelogenous leukemia patients may be expanded with FL. 16 Another important biological role for FL is its ability to stimulate the generation of dendritic and NK cells in vitro, in combination with other cytokines such as GM-CSF, TNF and TGF␤. In vivo, FL has been shown to stimulate the generation of dendritic cells in mice. Transgenic mice in which the FL gene has been disrupted show decreased numbers of their spleen dendritic cells and an alteration of the function of their spleen NK cells. [17] [18] [19] FL mRNA is expressed by a wide variety of hematopoietic and non-hematopoietic cells. 20, 21 FL can be produced as a membrane-bound molecule and as a soluble form likely to derive from the membrane via a proteolytic event.
Endothelial cells (EC) have been shown to produce many hematopoietic growth factors and may represent a useful model to study the regulation of their expression. In this report we show that they produce large amounts of soluble FL and express a membrane-bound form of this cytokine. We have analyzed the modulation of this production by IL-1 and glucocorticoids (GC). Both umbilical vein-derived endothelial cells (HUVEC) and bone marrow endothelial cells (BMEC) produce FL. We also used EC as a model to show that IFN-␣, MIP-1 ␣ and TGF-␤, up-regulate the production of FL. We studied the effects of the neutralization of FL in cocultures of hematopoietic progenitors with EC. Results showed that FL is a key cytokine for the generation of clonogenic cells in such a multicytokine context. Up-regulation of FL production is essential in explaining the effects of IFN-␣, MIP-1 ␣ and TGF-␤ on the generation of clonogenic cells.
Materials and methods

Cytokines and other reagents
Recombinant FL was a gift from Dr SD Lyman, Immunex Corp., Seattle, WA, USA. Monoclonal anti-FL antibody (clone 40406.111) and polyclonal anti-FL antibody (Cat. No. AF-308-NA) were purchased from R&D (Abingdon, UK). Monoclonal anti-FL antibody huFLT3L-M10 was a gift from Dr SD Lyman. MIP-1␣ was a gift from Genetics Institute, Cambridge, MA, USA. IFN-␣ was purchased from Roche (Roferon-A, sterile, apyrogenic solution for human therapeutic use; Neuillysur Seine, France). TGF-␤ was purchased from R&D. Neutralizing anti-TGF-␤ was purchased from R&D (Cat. No. MAB 240). Dexamethasone (DXM) sodium phosphate salt (sterile, apyrogenic solution for human therapeutic use) was purchased from Merck, Sharp and Dohme, Chibret (Paris, France). Hydrocortisone (HC) was purchased from Sigma (Saint Quentin Fallavier, France).
EC from the umbilical cord (HUVEC)
Primary cultures of HUVEC were obtained from freshly collected umbilical cords. 0.1% w/v collagenase (Boehringer Mannheim, Meylan, France) was used for treatment of the umbilical vein instead of 0.2%, as originally described. 23 HUVEC were cultured in IMDM (Iscove's modified Dulbecco's medium; Gibco, Cergy Pontoise, France) supplemented with 15% heat-inactivated fetal calf serum (FCS), penicillin (100 IU/ml), streptomycin (50 g/ml). Cells were grown to confluence in 75 or 25 cm 2 flasks coated with 100 g/ml collagen I (Jacques Boy Institute, Paris, France). Cells were passaged after treatment with trypsin-EDTA and routinely used between the second and fourth passages. Cells were identified by their characteristic morphology and by the expression of factor VIII antigen.
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EC from bone marrow microvasculature (BMEC)
EC from human bone marrow (BM) microvasculature (BMEC) were isolated following a two-step procedure with BNH-9 or S-Endo-1-coated microspheres. BNH-9 is a mouse IgM monoclonal antibody recognizing EC-specific H and Y antigens (Immunotech, Marseille, France). S-Endo-1 is a monoclonal antibody reactive with a 110 kDa protein expressed at the membrane of EC (Biocytex, Marseille, France). The whole procedure is essentially the same as described by Rafii et al 24 and Schweitzer et al. 25 BMEC were isolated by positive selection using BNH-9 or S-Endo-1 monoclonal antibody. This protocol gives a highly enriched population of BMEC. 25 EC were collected, washed once with complete medium and plated in collagen-coated dishes or flasks as above, on collagen Icoated 6-well Nunc plastic dishes in IMDM containing 20% FCS, 15 g/ml ECGF, 90 g/ml heparin, antibiotics and fungizone. Forskolin and IBMX (Sigma) were added at the beginning of the cultures at final concentrations of 0.5 M, to inhibit fibroblastic growth. 26 
Long-term bone marrow cultures (LTBMC)
LTBMC were established in 25 cm 2 tissue culture flasks from light-density bone marrow cells. Culture medium was IMDM with 12.5% FCS, 12.5% horse serum, penicillin (100 IU/ml), streptomycin (100 g/ml) and 10 −7 M hydrocortisone. Semiconfluent stromal layers were trypsinized, replated in 6-well plates and grown until confluency. Cells were then washed five-fold to remove hydrocortisone and incubated in IMDM plus 10% FCS and antibiotics (see Experimental procedures).
HBMEC cell line (TrHBMEC)
The HBMEC cell line was derived from primary cultures of human BMEC by intranuclear injection into preconfluent cells of a DNA construct consisting of a portion of the human vimentin promotor gene driving the SV40 early genes (T and t antigens); transfected cells were selected by growth potential in low serum medium lacking endothelial growth factors. The transfected cell line was maintained in IMDM containing 5% FCS, glutathione and antibiotics. 27 
Experimental procedures
Confluent HUVEC, BMEC, TrHBMEC or LTBMC monolayers were incubated in IMDM plus 10% FCS and antibiotics with the indicated stimuli, in 6-well plates. Cells were stimulated for the indicated time the supernatants were collected, centrifuged at 4°C, decanted into a fresh tube and kept at −80°C until assayed for FL.
CD34
+ cell isolation and cocultures with EC + cells were cocultivated with a HUVEC monolayer in a contact or non-contact system with transwell inserts essentially as described. 28 In some experiments, the HUVEC were prestimulated for 48 h with the indicated stimuli and washed four times before starting the coculture.
Hematopoietic colony assay
At the end of the culture period cells were counted, checked for viability by trypan blue exclusion and assayed for colony number. Colony assays were performed using the Methocult GF+ H4435 (StemCell Technologies, Meylan, France), (this assay detects granulocytic-monocytic, erythroid and multilineage colonies), following the manufacturer's recommendations. One thousand cells were plated. The plates were incubated at 37°C, 5% CO 2 and colonies were counted on day 14. Results were expressed either as the number of CFC for 10 5 cells or as the total number of CFC.
RNA isolation
Total RNA was isolated using RNAble from Eurobio (Les Ulis, France), following a procedure derived from the technique of Chomczynski and Sacchi 29 according to the manufacturer's instructions.
RT-PCR for FL
RT-PCR analysis was performed to look for the presence of FL mRNA in HUVEC using specific primers. RT-PCR was as follows. Single-stranded cDNA was produced by reverse transcription at 42°C for 60 min in 20 l reaction mixture containing 5 g of total cellular RNA, 1 × RT buffer (50 mM Tris-HCl, pH 8.3, 3 mM MgCl 2 , 75 mM KCl, and 10 mM dithiothreitol), 750 ng oligo d(T), (Gibco BRL), 500 M of dNTP mix (Gibco BRL), 40 U of Rnasin and 200 U of Superscript II (Gibco BRL). After heating at 85°C for 5 min, a quarter of the reverse transcription product was amplified in 53 l reaction mixture consisting of 1 × Taq reaction buffer (Gibco BRL), 100 M of dNTP mix (Gibco BRL), 20 pM of the sense (nucleotides: 5Ј-ATGACAGTGCTGGCGCCAGCCTGG-3Ј) and antisense (nucleotides: 5Ј-GGCCGGGGACCTCCGGTGTCGGGG-3Ј) primers and 5 U Taq polymerase (Gibco BRL). Thirty-one cycles of amplification were then performed at 94°C for 30 s for denaturation, at 65°C for 30 s for annealing and finally at 72°C for 1 min for extension on a Perkin Elmer Cetus DNA Thermal Cycler, (Perkin Elmer, Paris, France). Amplified products were revealed in an ethidium bromide-stained gel. Specificity of the amplified product was confirmed by cloning and sequencing the insert.
Cloning of RT-PCR products
The 600 bp fragment obtained after the RT-PCR step was directly cloned in pGEM-T (Promega, Charbonnières, France). Sequencing was done from both ends using the pGEM-T internal primers with the Oncor sequencing kit (Appligene Oncor, Illkirch, France). DNA and protein sequence analysis were performed with the DNAsis software package.
Immunofluorescence
EC were left to adhere on collagen-or FCS-coated 8-well microslides. They were fixed with cold methanol for 10 min, washed three times with PBS and blocked for 45 min with 2.5% FCS in PBS. Then, EC were incubated with monoclonal anti-FL antibody for 30 min at room temperature, washed and incubated with secondary fluorescein isothiocyanate (FITC)-labelled anti-mouse antibody (Sigma) for 30 min at room temperature. Control wells were incubated with combinations of corresponding isotypic antibodies at the same protein concentrations. Coverslips were mounted with anti-fade medium, sealed and examined with an Olympus BX 60 microscope. 
Flow cytometry analysis
Northern blot analysis
Total cellular RNA was extracted from HUVEC monolayers as described above (RNA isolation). RNA was denatured using formamide and formaldehyde and electrophoresis was performed on gels containing formaldehyde. Double-stranded cDNA probes were: (1) the human FL cDNA cloned as described above (cloning of RT-PCR products) excised from the pGEM-T as a ApaI/SpeI insert, (2) a human GAPDH cDNA from ATCC. Probes were labelled with 32 PdCTP by random priming (Boehringer Mannheim, Meylan, France). RNA loading was checked by ethidium bromide staining and control hybridization of the blot with the GAPDH probe.
ELISA
The monoclonal anti-antibody (clone 40406. 111; R&D), diluted at 10 g/ml in carbonate buffer pH 9.6, was coated overnight at 4°C, or 2 h at room temperature on 96-well microplates (Maxisorp, Nunc, Denmark). After washing three times with PBS-Tween 20, 0.1% (PBS-T), wells were added with 50 l assay diluent (RD1-20; R&D), and 200 l cell supernatants and incubated for 2 h at room temperature. After three washes with PBS-T, the polyclonal anti-FL antibody diluted 5 g/ml in PBS-BSA 1% was allowed to react for 1-2 h at room temperature before washing three times with PBS-T. A peroxidase-labelled mouse anti-goat antibody (Sigma) diluted 1/10000 in PBS-BSA was then added for 1 h at room temperature to the wells. The reaction was detected with tetramethyl benzidine (Sigma). Following coating, all incubations were conducted at room temperature. Optical densities were
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Western blot analysis
Cell supernatants (48 h conditioned medium), were analyzed by Western blotting following standard procedures. Briefly, samples from HUVEC conditioned medium were subjected to 12% SDS-PAGE under reducing conditions and electrotransferred to nylon membranes. Alternatively, FL was immunoprecipitated from the supernatants using polyclonal anti-FL antibody coupled to Sepharose 4B. Coupling of the antibody to Sepharose was performed according to the manufacturer's instructions (Sigma). Cell supernatants were added with 30 l of Sepharose 4B-antibody and incubated for 2 h at room temperature or overnight at 4°C. Beads were pelleted, washed five times with Tris 50 mM, NaCl 0.150 M, EDTA 1 mM, NP40 1%, boiled, subjected to 12% SDS-PAGE under reducing conditions and electrotransferred to nitrocellulose. Blots were developed using monoclonal anti-FL antibody and peroxidase-conjugated second antibody followed by chemiluminescence detection (Amersham, Les Ulis, France). Blocking buffer was 5% dried milk in PBS. Immunoprecipitation of the ligand with solid-phase polyclonal anti-FL antibody followed by Western blot analysis with the monoclonal anti-FL antibodies (either clone 40406. 111, R&D or huFLT3L-M10, Immunex) consistently gave a stronger signal.
Cytokine neutralization experiments
Neutralizing polyclonal antibodies directed against IL-1␣, IL-1␤, IL-6, LIF, G-CSF, GM-CSF and M-CSF were purchased from R&D systems (Cat No. AB-200-NA, AB-201-NA, AB-206-NA, AB-214-NA, AB-215-NA and AB-216-NA, respectively). Neutralizing polyclonal anti-LIF antibody was a kind gift from Pr V Praloran, CHU Dupuytren, Limoges, France. In preliminary experiments, 5 g/ml final concentration of each antibody was found to give an efficient neutralization of a combination of recombinant human IL-6, IL-1␣, IL-1␤, LIF, G-CSF, GM-CSF and M-CSF at concentrations of 50 ng/ml each (IL-6 and GM-CSF were gifts from Dr AS Blanc, Sandoz, Basel, Switzerland; M-CSF a gift from Cetus Corporation, Emeryville, CA, USA; G-CSF a gift from Dr McNiece, Amgen, CA, USA; LIF a gift from Pr JF Moreau, Bordeaux, France). In TGF-␤ neutralization experiments, EC were grown for 48 h in the presence or not of 5 g/ml of neutralizing anti-TGF-␤ antibody.
Statistics
Results of experimental points obtained from multiple experiments were reported as the mean ± s.e.m. Significant differences between values obtained in each assay were determined by unpaired Student's t-test for samples with equal variance. Differences were considered as significant when P Ͻ 0.05.
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Results
Expression of FL messenger RNA by EC. FL mRNA is a stable message in HUVEC
RT-PCR analysis was first performed to check for the presence of a possible FL mRNA transcript in HUVEC. Total RNA was isolated from HUVEC and analyzed after reverse transcription and amplification with FL-specific primers. An amplified band corresponding to the expected size could be evidenced. Positive control was total RNA isolated from human mononuclear cells. To confirm specificity, the amplified product was cloned and sequenced. Sequence analysis confirmed that the insert was identical to FL (not shown).
To analyze the regulation of the expression of FL mRNA, we performed Northern blots using the whole amplified product as a probe. Total RNA from HUVEC either in basal conditions or after stimulation with IL-1␣ or DXM were studied. Loading was controlled after reprobing the blot with a GAPDH probe. Results showed the presence of a single 1.3 kb FL transcript in HUVEC (Figure 1 ). IL-1␣ moderately (average of five-fold, two experiments) augmented its expression ( Figure 1, lane B) . GC effects were also studied as they are known inhibitors of the production of a number of hematopoietic growth factors. DXM did not alter the expression of FL message. It did not inhibit its IL-1␣-induced augmentation (Figure 1, lanes C and D) .
The kinetics of the degradation of FL mRNA was analyzed at time-intervals after actinomycin D addition. Results showed 
Large amounts of soluble FL are produced by EC and not by LTBMC. Modulation by IL-1 and GC
The production of soluble FL by HUVEC was demonstrated by Western blotting. FL derived from EC supernatants comigrated with the recombinant soluble form of the ligand at 25 kDa (shown with HUVEC in Figure 3a , similar results were obtained with BMEC or TrBMEC supernatants). The fainter high molecular weight band probably corresponds to heterogeneous glycosylation.
ELISA measurements of the ligand (Figure 3b) showed that confluent HUVEC produced above 100 pg/ml/48 h of FL in 6-well plates. Confluent primary cultures of BMEC and the BMEC-derived cell line TrBMEC produced similar amounts. Baseline production of FL is augmented in BMEC and TrBMEC, however, not significantly. IL-1␣ or DXM moderately but significantly stimulated FL production by HUVEC (P = 0.01, P = 0.015 for IL-1␣ and DXM vs control, respectively), by BMEC (P = 0.005, P = 0.002 for IL-1␣ and DXM vs control, respectively) and by TrBMEC (P = 0.008, P = 0.04 for IL-1␣ and DXM vs control, respectively). In LTBMC culture supernatants FL was not detectable. The sensitivity of our ELISA being 30 pg/ml, these results suggested that FL production by LTBMC is low. The endogenous production of TGF-␤ by the EC was not responsible for the basal production of FL as neutralization of TGF-␤ led to a nonsignificant reduction of the production of FL.
Figure 2
Turn over of FL mRNA. Northern hybridizations were performed to study the half-life of FL mRNA in HUVEC. Cells at confluence were incubated in the presence of actinomycin D (10 g/ml) and mRNA was extracted at 1, 2 and 4 h. 
Expression of the membrane-bound form of FL by EC. Flow cytometry and immunofluorescence
TGF-␤, MIP-1␣ and IFN-␣ stimulate soluble FL production
The effect of TGF-␤, MIP-1␣ and IFN-␣ on FL expression were studied as these molecules are known regulators of primitive hematopoiesis. Working concentrations were 50 ng/ml for TGF-␤, 500 ng/ml for MIP-1␣ and 1000 IU/ml for IFN␣. HUVEC were stimulated for a period of 48 h. ELISA measurements (Figure 4a ), showed an augmentation of soluble FL production in the presence of TGF-␤ (1.5-fold increase, P = 0.012), MIP-1␣ (1.6-fold increase, P = 0.012), and IFN-␣ (1.75-fold increase, P = 0.03) (average of four experiments). Identical results were obtained with TrBMEC.
TGF-␤, MIP-1␣ and IFN-␣ stimulate membrane-bound FL expression
The modulation of membrane-bound FL by TGF-␤, MIP-1␣ and IFN-␣ was studied by flow cytometry. There was a consistent and clear up-regulation of membrane-bound FL by TGF-␤ and IFN-␣ (Figure 4b ).
Neutralization of FL in EC/hematopoietic cocultures accelerates the differentiation of the progenitors
To study the production and the regulation of the production of FL in an experimental system that would reflect more closely the physiologic hematopoiesis, we performed coculture experiments of CD34 + progenitor cells with an EC monolayer. Preliminary experiments showed that the presence of the proliferating and diffentiating progenitors did not influence the production of FL by the EC monolayer (not shown).
In an effort to assess the functional relevance of the production of FL by EC, we carried out coculture experiments in which the biological activity of FL was inhibited with a neutralizing polyclonal antibody. CD34
+ hematopoietic progenitors were cocultured in non-contact with a HUVEC monolayer. According to the manufacturer's instructions the antibody neutralizes 100% FL when used at a concentration (w:w) 20-fold higher than FL. The neutralizing antibody was used at a concentration of 5 g/ml, which is approximately 5 × 10 (CFC for  10 5 cells), cell proliferation and the total number of CFC showed that in control cocultures the neutralization of FL had no effect on cell proliferation (average of 310-fold in control cultures (total average number of cells generated at day 21: 6.25 × 10 6 ) and 305-fold in cultures treated with anti-FL (five experiments)), whereas a strong reduction in the total CFC was observed therefore resulting in a reduction of the frequency of CFC (results illustrated in Figure 5a and b) . We also studied what would be the results of additional neutralization of FL when IL-6, LIF, G-CSF, GM-CSF and M-CSF, cytokines known to be produced by EC, were being neutralized. Neutralization of IL-6, IL-1␣, IL-1␤, LIF, G-CSF, GM-CSF and M-CSF led to a profound reduction in the total CFC number because of a strong inhibition of cell proliferation (reduction by an average of 9.8-fold, five experiments). The frequency of CFC was increased. Additional neutralization of FL, however, again resulted in a strong reduction in the total number and the frequency of CFC. Similar results were obtained in contact coculture settings and in cultures supported with the EC cell line TrBMEC (not shown). Morphological analysis showed a shift towards more mature cells when FL was being neutralized (nearly all the cells being promyelocytes, myelocytes, metamyelocytes and monocytes in the presence of the anti-FL antibody, while there was 40% more immature cells (less than 10 granulations) in the control). Phenotype of the expanded cells tended to indicate the same phenomenon, namely that in the presence of the neutralizing anti-FL antibody the cell population was more mature (higher expression of CD11b, CD14 and CD 16 (fluorescence ratios 2,6, 1,5 and 2,2, respectively, average of three experiments). Addition of exogenous FL at a concentration of 100 ng/ml to the cocultures had no effect on cell proliferation and led to an increase in both the frequency and the total number of CFC (average of 1.7-fold and 1.6-fold respectively, two experiments). Again, neutralization of FL (anti-FL at 5 g/ml) reduced both figures to control levels. Therefore, neutralization of FL in the cocultures resulted in an accelerated maturation of the progenitors and a loss in clonogenicity.
Modulation of CFC generation by IFN␣, MIP1-␣ and TGF-␤: role of the enhancement of FL production
To determine the functional implication of the stimulation of FL production in the effects of IFN-␣, MIP1-␣ or TGF-␤ on hematopoiesis, we studied the modulation of the production of CFC by these mediators in CD34 + /HUVEC 21 days noncontact cocultures while FL was neutralized. To eliminate direct influence of IFN-␣, MIP1-␣ or TGF-␤ on the progenitors, HUVEC were prestimulated for 48 h with these mediators and then washed before starting the coculture (day 0). FL concentrations were nearly identical in the supernatants of prestimulated HUVEC or HUVEC that were grown in the continuous presence of IFN-␣, MIP1-␣ or TGF-␤ (88, 140, 136, 135 pg/ml/10 6 cells in control, IFN-␣, MIP1-␣ or TGF-␤, respectively at day 4 and 89, 145, 138, 139 pg/ml/10 6 cells in control, IFN-␣, MIP1-␣ or TGF-␤, respectively at day 10, in prestimulated HUVEC (average of n = 3 experiments). Comparative measurements of the effects of FL neutralization on the frequency of CFC cell proliferation and the total number of CFC showed that the neutralization of FL inhibited both the frequency and the total number of CFC in IFN-␣, MIP1-␣ or TGF-␤ cultures (results illustrated in Figure 6a and b). Control antibody had no effect. Morphological analysis confirmed these results showing a shift towards late progenitors and mature cells in the presence of the antibody (not shown).
Discussion
EC are a known source of hematopoietic growth factors that explains their capacity to support the proliferation and the differentiation of hematopoietic progenitors. 28 FL receptor is a recently discovered member of the class III tyrosine kinase receptor family 30 that includes c-kit, c-fms, the receptors for SCF, M-CSF, and PDGF. In vitro as well as in vivo data indicate that FL has profound effects on the regulation of primitive hematopoietic progenitor cells. FL stimulates the proliferation of primitive progenitors. It is the most potent known stimulus of the proliferation of LTC-IC.
In this study we showed that EC represent a quantitatively important source of FL. Our report on the in vitro very low
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Figure 6
Role of the enhancement of FL production in the modulatory effect of IFN-␣, MIP-1␣ and TGF-␤ on clonogenic cell generation. Human CD34 + cells were cocultured for 21 days in non-contact with HUVEC that had been prestimulated for 48 h with IFN-␣ (1000 IU/ml), MIP1-␣ (500 ng/ml) or TGF-␤ (50 ng/ml), in the presence or not of a neutralizing anti-FL polyclonal antibody (aFL) (or control antibody (control Ab)). Half of the medium was changed every 5 days with readdition of the antibody. At the end of the coculture period either (a) the frequency (CFC number for 10 5 cells) or (b) the total number of CFC was assayed. Significant results are shown (*). levels of FL production by human LTBMC or bone marrowderived fibroblasts extent findings by Lisovsky et al 21 who found undetectable production of FL by LTBMC in vitro. The nature of the cells involved in this production remains to be elucidated. The bone marrow stroma is made up of approximately 60-70% fibroblasts and 10-20% of EC and other cells present in small amounts but with potential functional importance such as adipocytes, macrophages and osteoclasts. 31 EC are part of the bone marrow stromal microenvironment. [32] [33] [34] [35] [36] [37] We therefore propose that EC can represent a major cell source for this cytokine in the bone marrow.
A membrane-bound form of the ligand is expressed on EC. One single message was detected ruling out the presence of alternatively spliced mRNAs, within the limits of the Northern blot sensitivity. The soluble form of FL is therefore likely to derive from the membrane-bound species via a proteolytic event. FL like kit ligand and M-CSF are made as a membranebound species that need to be processed to yield a soluble activity.
1,2,22 IL-1␣ stimulates the expression of FL mRNA in EC. IL-1 has also been shown to stimulate FL mRNA expression in bone marrow stromal cells. 21 The IL-1-induced stimulation of FL production may explain the increased capacity of IL-1-stimulated EC to support the proliferation of CFC. 28 We also studied the effect of GC as they are known inhibitors of the production of a large number of hematopoietic growth factors. GC do not alter FL mRNA expression, however, they have been shown to decrease the expression of a number of hematopoietic growth factor mRNAs, among which are IFN-␤, 38 TNF-␣, 39 IL1-␤, 40 GM-CSF, IL-8, IL-6 41 or LIF. 42 Interestingly, M-CSF and SCF, two other cytokines that are ligands for a common family of tyrosine kinase receptors, are not down-regulated by GC, 41, 43 whereas most of the other hematopoietic growth factors are inhibited by GC. There was, instead, a consistently higher concentration of FL in the supernatants of DXM-stimulated HUVEC compared to control cells. There may be an internal pool of FL that can be at least partially mobilized by GC. The existence of such an intracellular mobilizable reservoir of FL in peripheral blood and bone marrow mononuclear cells has been suggested by Chklovskaia et al. 44 Another explanation may be that DXM up-regulates the expression of the protease involved in the release of FL from the cell surface explaining the increased release of the ligand. More generally, inhibition by GC of the production of cytokines that drive the differentiation of hematopoietic progenitors while they stimulate the expression of SCF 43 and FL, may explain why more primitive CFC in cocultures EC/CD34
+ progenitors are generated in the presence of GC 28 or the protective effects that GC appear to have on the primitive progenitors. 45 The role of the regulation of the production of FL by GC or IL-1 in mediating their biological effects is an interesting question and deserves further investigation.
The stimulation of FL expression by IFN-␣, MIP-1␣ or TGF-␤ may be important to understand how these mediators are able to modulate the proliferation and differentiation of hematopoietic progenitors. The stimulation of FL production by IFN-␣ contrasts with the inhibition of the production of GM-CSF, G-CSF 46 or IL-11. 47 This differential effect strongly suggests that IFN-␣ has the differential ability to down-regulate the production of cytokines committing cells to differentiation while it stimulates the production of regulators of primitive hematopoiesis such as FL (this study) or MIP1-␣. 48 In HUVEC/CD34 + progenitor cell cocultures, IFN-␣, MIP-1␣ or TGF-␤ stimulated the generation of CFC. Neutralization experiments demonstrated that the enhancement of FL production by IFN-␣, MIP-1␣ or TGF-␤ played a significant role in this stimulation. These results strongly suggest that, apart from the direct effect of these molecules on the hematopoietic progenitors, the action of IFN-␣, MIP-1␣ or TGF-␤ is also indirectly mediated through regulation of the production of FL by the stromal cells. The overall increase in soluble FL that is induced by these mediators remains moderate but the proteolytic release of the ligand probably represents a rate limiting step; this would explain, for instance, the dissociation between expression of the FL mRNA and soluble FL in IL-1␣ stimulated cells. MIP-1␣ and TGF-␤ were first described as having a direct inhibitory activity on the initial stages of proliferation of early hematopoietic progenitors in vitro. However, the action of MIP-1␣ or TGF-␤ may be inhibitory or stimulatory on the proliferation of hematopoietic progenitors depending on the differentiation stage of the progenitors and/or the presence of other cytokines. [49] [50] [51] [52] [53] [54] In a stromal culture context, MIP-1␣ was found together with IL-3 and diffusible factors produced by the stromal cells to support the growth of human LTBMC-initiating cells. 55 Discrepancies observed may reflect indirect effects of these mediators via release of cytokines by accessory cells or stromal cells.
FL neutralization experiments in EC/CD34 + progenitor cocultures shed further light on the role of EC-derived cytokines in the control of hematopoiesis in vitro. Clearly, in such a coculture context, FL produced by EC is instrumental in expanding clonogenic cells, since its neutralization leads to an accelerated maturation of the progenitors, while cytokines such as G-CSF, GM-CSF and M-CSF are pushing cells to differentiate and to proliferate. Cytokine neutralization experiments tend to confirm this as cytokine neutralization led to a strong reduction in cell proliferation and an increase in clonogenicity. Residual CFC after neutralization of FL may result from incomplete neutralization but is more likely to result from the presence of other cytokines involved in CFC generation such as SCF, for instance. 56 These experiments also show that the action of FL must always be interpreted within a multi-cytokine context. Indeed, EC-derived cytokines when acting altogether are not able to maintain an expansion of clonogenic progenitors for more than 3 weeks, 28 although they are producing FL and SCF. In this in vitro system it is likely that the combined presence in high concentrations of late acting cytokines such as G-CSF, GM-CSF or M-CSF push the cells towards differentiation. Alternatively, the lack of production of cytokines acting in synergy with FL to maintain or expand clonogenic cells might be the explanation. We found, for instance, that thrombopoietin could not be detected by ELISA in EC culture supernatants, the production of this crucially important cytokine in the FL-induced expansion of clonogenic cells 12, 57 being therefore either lacking or too low to be detected (unpublished results). Finally, the production of FL by EC provides a potentially useful model to study the synthesis, processing and control of secretion of this cytokine.
